|
CN106632501A
|
|
Rhodium-diphosphine ligand tetrafluoroborate and preparation method thereof
|
|
WO2016202232A1
|
|
Synthesis method for (4s)-n-boc-4-methoxy methyl-l-proline amine salt
|
|
CN106256819A
|
|
A kind of synthetic method of (4S) N Boc 4 methoxy L proline amine salt
|
|
CN106883185A
|
|
A kind of preparation method of the chloro- 2- trifluoromethyl pyrimidines of 4-
|
|
CN106316803A
|
|
SGLT-2 inhibitor intermediate synthesis method
|
|
CN105801462A
|
|
(4S)-N-Boc-4-methoxymethyl-L-proline synthesis method
|
|
CN105801518A
|
|
(S)-1-Boc-3-hydroxypiperidine synthesis method
|
|
CN104530000A
|
|
Method for preparing aldosterone synthase conditioning agent intermediate
|
|
CN104557917A
|
|
Preparation method of 5-halogenated azacycloindole
|
|
CN104496795A
|
|
Method for preparing DGAT-1 inhibitor intermediate
|
|
CN104744227A
|
|
5-bromine-2-chlorobenzaldehyde preparation method
|
|
CN104693108A
|
|
Preparation method of Bruton's tyrosine kinase (Btk) intermediate
|
|
CN104418834A
|
|
Synthetic method of an antidiabetic drug intermediate
|
|
CN104370769A
|
|
Preparation method of hydroxyadamantylglycine derivative
|
|
CN103804208A
|
|
Method for preparing drug intermediate for hepatitis c
|
|
CN103664564A
|
|
Preparation method of analgesic intermediate compound
|
|
CN102531932A
|
|
Preparation method of important intermediate of hepatitis c virus (HCV) protease inhibitor
|
|
EP2602250A1
|
|
Method for preparing rosuvastatin calcium intermediate
|
|
CN102212082A
|
|
Rosuvastatin calcium intermediate and preparation method thereof
|
|
CN101735272A
|
|
Method for preparing rosuvastatin calcium midbody
|
